Periostin and periostin-like factor in the human heart: possible therapeutic targets

Background gh numerous signaling pathways have been identified in adult heart disease, our ability to diagnose and treat human cardiomyopathies remains limited. A family of proteins, which includes periostin and periostin-like factor (PLF), has been identified during heart development and disease. Based on recent findings, these proteins are candidate therapeutic agents for heart disease. s trix GeneChip Expression Analysis as well as northern and western blot analyses were used to determine periostin and PLF expression in humans. Periostin-like factor levels were determined, by western blot analysis, in the rat animal model used to study myocardial loading and unloading. In vivo and in vitro effects of overexpressing PLF by infection with adenovirus were assessed by calculating cardiac myocyte cross-sectional area and determining the level of protein synthesis, respectively. s and Conclusions ndings on PLF suggest that this periostin isoform plays a crucial role in adult cardiac myocyte growth following mechanical overload, thus, implicating its potential as a therapeutic target. In addition, we believe that the differences between the periostin and PLF are of functional significance.